Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma
| Autor: | S B Jennings, M. M. Walther, W. M. Linehan, P. L. Choyke, Steven A. Rosenberg, Richard B. Alexander, Kathy Hurley, Andrich M |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Nephrology
medicine.medical_specialty Pathology Necrosis Urology medicine.medical_treatment Renal cell carcinoma Internal medicine medicine Carcinoma Animals Humans Carcinoma Renal Cell Chemotherapy Kidney business.industry Tumor Necrosis Factor-alpha medicine.disease Prognosis Kidney Neoplasms medicine.anatomical_structure Chemotherapy Cancer Regional Perfusion Sarcoma medicine.symptom business Perfusion |
| Zdroj: | World journal of urology. 14 |
| ISSN: | 0724-4983 |
| Popis: | Patients with localized renal-cell carcinoma who are candidates for renal parenchymal sparing surgery are being treated with isolated renal perfusion with recombinant human tumor necrosis factor (TNF). Isolated organ perfusion is a surgical technique that allows a cancer-bearing organ or region of the body to be treated with high doses of chemotherapy or biologic, agents that would not be tolerated systemically. In patients with in-transit melanoma or unresectable sarcoma, treatment with hyperthermic isolated limb perfusion using TNF, interferon-gamma, and melphalan has resulted in response rates exceeding 90%. Because preclinical studies suggest that TNF may induce regression of tumors by causing hemorrhagic necrosis mediated by effects on tumor-related vascular endothelium, a vascular tumor such as renal-cell carcinoma could potentially be very responsive. A phase I study of escalating TNF doses delivered via isolated renal perfusion is currently being conducted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink